**1. Introduction**

Infertility is a worldwide health problem with one in six couples suffering from this condition and with a major economic burden on the global healthcare industry. Estimates of the current global infertility rate suggest that 15% of couples are infertile (Zegers-Hochschild *et al.,* 2009) defined as: (1) failure to conceive after one year of unprotected sexual intercourse (i.e. infertility); (2) continual failure of implantation at subsequent cycles of assisted reproductive technology; or (3) persistent miscarriage events without difficulty conceiving (natural conceptions). Tubal factor infertility is among the leading causes of female factor infertility accounting for 7-9.8% of all female factor infertilities. Tubal disease directly causes from 36% to 85% of all cases of female factor infertility in developed and developing nations respectively and is associated with polymicrobial aetiologies. One of the leading global causes of tubal factor infertility is thought to be symptomatic (and asymptomatic in up to 70% cases) infection of the female reproductive tract with the sexually transmitted pathogen, *Chlamydia trachomatis*. Infection-related damage to the Fallopian tubes caused by *Chlamydia* accounts for more than 70% of cases of infertility in women from developing nations such as sub-Saharan Africa (Sharma *et al.,* 2009). Bacterial vaginosis, a condition associated with increased transmission of sexually transmitted infections including those caused by *Neisseria gonorrhoeae* and *Mycoplasma genitalium* is present in two thirds of women with pelvic inflammatory disease (PID). This review will focus on (1) the polymicrobial aetiologies of tubal factor infertility and (2) studies involved in screening for, and treatment and control of, Chlamydial infection to prevent PID and the associated sequelae of Fallopian tube inflammation that may lead to infertility and ectopic pregnancy.
